Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrecizumab in Early Septic Shock (AdrenOSS-2)
NCT03085758Phase 2Completed
- Sponsor
- Adrenomed AG
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- IgG Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of adrecizumab in septic shock, sponsored by Adrenomed AG. Started Dec 2017; status: completed.
02
Drugs
adrecizumab
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03085758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085758.